The pathophysiology of acute GvHD (aGvHD) involves presentation of Ags from damaged tissue by host APCs to donor T cells, triggering a cytokine storm. Inhibiting this pro-inflammatory cellular response through corticosteroids and other immune suppressive medications has thus been the cornerstone of treatment of aGvHD. 1, 2 We recently reported that patients at the onset of aGvHD exhibit low-circulating levels of a factor important for tissue repair -epidermal growth factor (EGF)-with even lower EGF levels in patients, who do not respond to steroids. EGF, secreted from the salivary glands and duodenum, has a major role in epithelial cell proliferation and cytoprotection following mucosal damage. 3 We sought to determine the impact of EGF on clinical outcomes at day +100 post allogeneic hematopoietic cell transplantation (HCT) in adult recipients (n = 101) of allogeneic HCT at the University of Minnesota Medical Center.
We measured serum EGF levels at day +100 after transplantation by magnetic bead array using the MILLIPLEX (Millipore, Billerica, MA, USA) assay (EGF levels detectable at ⩾ 0.2 pg/mL) and determined associations with clinical and laboratory variables. Statistical analysis was performed using JMP 11.2.0 (SAS institute, Cary, NC, USA). Wilcoxon rank sum-tests were used to determine univariate association of EGF levels and other clinical variables. Spearman's rho was used for nonparametric correlations of EGF levels and other clinical variables. Kaplan-Meier estimates were used to estimate 2-year survival. Multivariate survival analyses of overall survival were performed using Cox proportional hazards. Receiver operating characteristic (ROC) analyses were performed to assess the role of clinical factors (age, maximum aGvHD grade and platelet counts) with EGF levels on a 2-year OS.
Patients (n = 101) all underwent HCT for hematologic malignancies between 2010 and 2013. Fifty eight percentage were male, 71% received nonmyeloablative conditioning, and donor source was matched related donors (45%), umbilical cord donors (42%) or unrelated adult donors (13%). Median EGF level was 90.6 pg/mL (interquartile (IQR) range 28.8-152.4 pg/mL) at day +100 after allogeneic transplant. Levels of EGF at day +100 did not show a significant relationship with age, underlying diagnosis, donor type or conditioning intensity (not shown). serum sample collection. Day +100 serum EGF was 42-fold lower in patients with prior aGvHD grade III-IV, compared with grade I-II aGvHD or no aGvHD before day +100 (median EGF 51 pg/mL versus 122 pg/mL, P = 0.0036) as shown in Figure 1a . On singleorgan analysis, EGF levels were NS associated with the presence of skin (n = 30, median 108 pg/mL, P = 0.1), liver (n = 2, median 45 pg/mL, P = 0.3) or lower GI aGvHD (n = 28, median 55 pg/mL, P = 0.2), but were nearly threefold lower in patients with upper GI aGvHD compared with the absence of upper GI aGvHD versus no upper GI involvement (n = 20, median EGF 43 pg/mL versus 119 pg/mL, P = 0.007; Figure 1b) , respectively. As isolated upper GI GvHD was a relatively uncommon finding in our study (n = 4), most patients with low EGF and upper GI aGvHD had other organ involvement of aGvHD as shown in Supplementary Information. Of the four patients in our analysis with isolated upper GI GvHD, three had EGF levels o 75 pg/mL. We suspect that upper GI involvement may be underestimated, as on chart review of patients with isolated lower GI (n = 6) and skin (n = 16) GvHD, many patients with lower EGF levels o 75 pg/mL did not undergo diagnostic testing for GI GvHD and were not formally classified as having this diagnosis, but had suggestive clinical signs and symptoms such as nausea and anorexia that improved with steroids.
Of 52 patients treated for aGvHD, 32 had complete response (CR, 61.5%), 18 had partial response (PR, 34.6%) and 2 did not have a response (NR, 3.8%) at 28 days after initiation of steroids (Figure 1c) . Patients without aGvHD who served as controls showed the highest EGF levels (median 100.2 pg/mL, IQR 50-170 pg/mL). Patients with aGvHD who had a CR (n = 32, median EGF 87 pg/mL, IQR 37-167 pg/mL) had similar EGF levels, as patients with PR to first-line therapy with corticosteroids (n = 18, median 89 pg/mL, IQR 20-169 pg/mL). Due to low numbers of non-responders to aGvHD treatment at 28 days, we were unable to draw conclusions regarding their EGF levels.
Six patients developed chronic GvHD. There was a trend toward lower EGF levels at day +100 being associated with subsequent chronic GvHD (median EGF 58 pg/mL with chronic GvHD versus 102 mg/mL without chronic GvHD, P = 0.056). Of the six patients who went on to develop chronic GvHD, five had prior aGvHD. There was no correlation between EGF levels and remission or relapse of disease at day +100 (median EGF 101 pg/mL in CR/PR versus 52 pg/mL in relapsed disease, P = 0.25).
Univariate analysis of serum EGF levels475 pg/mL at day +100 were associated with improved 2-year survival (P = 0.01) with 77% surviving with EGF475 pg/mL versus 52% surviving with EGF ⩽ 75 pg/mL at 2 years. Multivariate analysis of age, aGvHD grade and EGF ⩽ 75 pg/mL using Cox proportional hazards analysis of survival showed that EGF ⩽ 75 and platelets ⩽ 100 × 10 9 /L as a composite variable had a 3.8-fold increase of death (95% confidence interval 1.4-10.8, P = 0.01) on multivariate analysis (Figure 2 ). However, patients with EGF475 pg/mL and thrombocytopenia did not have statistically inferior survival. Previous ROC analyses showed that EGF is a reasonable biomarker of aGvHD with an area under the curve (AUC) of 0.77. 4 ROC analyses in this cohort day +100 EGF showed that serum EGF alone is a poor discriminator of OS with an AUC of 0.6, although the addition of EGF to conventional characteristics (age and maximum grade of aGvHD) and platelet counts slightly increased the AUC from 0.72 to 0.75 (Figure 2b ). Taken together, our data suggest that patients with low day +100 EGF levels in the setting of conventional risk factors for death may have a particularly poor prognosis.
Low EGF levels at the onset of aGvHD were previously observed in our study of angiogenic growth factors. 4 Here we demonstrate that low EGF levels are present on day +100 in patients with aGvHD, particularly with upper GI involvement, before this time point. Mechanistically, a plausible explanation for this may be decreased production of EGF through destruction of Brunner's glands in the duodenum due to inflammation, or consumption during epithelial regeneration. Further studies to determine the mechanism of low EGF after aGvHD are needed.
The type of sample analyzed-serum versus plasma-greatly impacts EGF levels. EGF levels have previously been demonstrated to be elevated in platelet-rich versus platelet-poor plasma. 5 Platelet counts were positively associated with serum EGF levels (Spearman's rho 0.58, P o 0.0001) in our study. Future studies should use plasma samples if possible as we verified in a separate cohort (n = 26, including 10 healthy controls and 16 post-HCT patient samples) a lack of correlation of plasma EGF and platelets (Spearman's rho 0.17, P = 0.4).
EGF association with aGvHD has therapeutic implications as this provides an adjunctive target for treatment through replacing a potentially important component of mucosal healing. Our study has established an association between EGF levels and prior gastrointestinal GvHD, which has importance given the role of EGF on epithelial cell proliferation after mucosal damage.
6-8 EGF supplementation has been studied in the treatment of other diseases involving mucosal injury, including inflammatory bowel disease, 9 peptic ulcer disease 10 and neonatal necrotizing enterocolitis. 11 The safety of EGF administration in the HCT setting needs to be assessed given EGF receptor overexpression and mutation in some malignancies. 12 Although EGF has not induced dysplasia in mouse models, 13 the potential for carcinogenesis and worsening hematologic disease control still needs to be carefully evaluated.
EGF receptor (EGFR) inhibitors are in widespread clinical use today for the treatment of epithelial malignancies. It is likely not a coincidence that EGFR inhibitors have a side effect profile, including rash, hepatotoxicity and diarrhea that mimics symptoms of acute aGvHD.
14 Our report suggests that low EGF after the onset of aGvHD may be a previously unrecognized component of aGvHD pathophysiology amenable to therapeutic intervention. As it is yet unknown whether a low EGF state is a contributing factor or end result of aGvHD, further studies should focus on the temporal relationship of EGF levels with respect to development of aGvHD.
